RxDoctor Payments Data

Sarah Nance

Family · Lima, OHNPI 1841967288

Payments from drug & device makers

$7,326in general payments, 2019–2025

Across 353 payments — averaging $20.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$963
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$519
  • Sanofi$479
  • Johnson & Johnson$338
  • Aimmune Therapeutics, Inc.$323
  • plus $3K from 29 others

What the payments were for

  • Food & beverage$7,293100%
  • Education$330%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,326 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$55,176
Medicare patients
398
Services billed
549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase19$39,774
LinzessLinaclotide26$25,913
Mesalamine12$8,959
Dexlansoprazole DrDexlansoprazole24$4,246
Pantoprazole Sodium81$1,690
Famotidine120$1,156
Sucralfate22$507
Sulfasalazine22$471
Dicyclomine Hcl26$390
Omeprazole45$319
Metronidazole11$137

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$323$39,77419 claims
AbbVieLinzess$1,557$25,91326 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Lima

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →